Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.
Por:
Llombart-Cussac A, Fernandez-Murga L, Martinez E, Santaballa A, Bermejo B, Rodríguez-Lescure A, Iranzo V, de la Morena P, Iranzo-Barreira J, Cortes J, Riva F, García J, Dustin D, Vidal-Martinez J, Liébana S, Serrano-Garcia L, Cejalvo J
Publicada:
1 jun 2025
Resumen:
|